InNexus to Present at International Bio Ventures Conference
March 18 2005 - 11:54AM
PR Newswire (US)
InNexus to Present at International Bio Ventures Conference TSX.V:
IXS OTC BB: IXSBF VANCOUVER, March 18 /PRNewswire-FirstCall/ --
InNexus Biotechnology Inc. is pleased to announce it has been
selected to speak at the 5th Annual EC 21 Bio Ventures Conference
to be held March 22-23 in London, England at the Queen Elizabeth II
Conference Centre at 1:45 pm. Additionally, the Company's business
plan has been selected from an international assemblage of
submissions as one of three finalists for the Best in Show -
Business Plan Competition being held in conjunction with the
Conference. The InNexus presentation will include an overview of
Super Antibody Technology, current partnership and co-development
activity, recent expansion of its development program and lab
facilities, and the strategic direction of the company. "The EC 21
meeting continues our exposure to the financial community while
allowing our technology and business plans to be showcased before a
large international audience of investors," commented Dr. Charles
Morgan, President and CEO of InNexus. The Technology Vision Group
LLC and Ferghana Partners Group, co-sponsors of the Business Plan
"Best in Class" event, have organized the competition for life
science companies to compete via their business plans and
presentations. This highly competitive event utilizes a
multi-disciplined panel to judge the "investment merits" of three
finalists and award The 2005 EC21 BioVentures Best in Show Award.
About EC 21 The mission of the European C21 BioVentures (EC21)
conference is to educate all stakeholders in the bioscience
industry about the trends that are driving its growth and
development in the 21st century. The conference was first held in
2000 in London and has evolved into an annual gathering to explore
the future of investing in biotechnology. The EC21 conference
attracts leading technology experts, investors and company
executives to meet informally, exchange ideas and to review the
business goals of innovative new companies in the fields of
biotechnology, informatics, medical devices and healthcare.
Representatives in attendance include: senior executives from Big
Pharma, life science companies, entrepreneurs, scientists,
technology transfer experts, investment fund and asset managers,
investment and commercial bankers, corporate finance specialists,
equity analysts, venture capitalists, high net worth private
investors, and government officials working in the area of
technology and industrial development. In addition, representatives
from leading service providers and the media will also attend. For
more information please visit http://www.techvision.com/ec21/about
About InNexus InNexus Biotechnology Inc. is an innovative
antibody-driven drug development company that has developed two
technology platforms, SuperAntibody(TM) and TransMAbs(TM), which
respectively improve the potency of existing antibody products and
create a novel class of antibody based drugs which can penetrate
into cells. Both product platforms utilize unique, novel and
patented methods and technologies allowing InNexus (and its
strategic partners) to advance novel drug therapeutics and
diagnostics to create new markets within multiple disease areas. To
learn more about InNexus please visit
http://www.innexusbiotech.com/ This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements are not
historical facts and are subject to risks and uncertainties which
could cause actual results and the timing of certain events to
differ materially from those set forth in or implied herein
including, without limitation, risks associated with clinical
development, regulatory approvals, product commercialization,
intellectual property claims litigation and other risks associated
with the Company's proposed activities. On behalf of the Board of
Directors of InNexus Biotechnology, Inc. "ALTON C. MORGAN" Dr. A.
Charles Morgan President Investor Relations: Toll-free:
1-866-990-8382 or 1-888-271-0788 The TSX Venture Exchange has
neither approved nor disapproved of the information contained
herein. DATASOURCE: InNexus Biotechnology, Inc. CONTACT: Investor
Relations: Toll-free: 1-866-990-8382 or 1-888-271-0788,
Copyright